Apolipoprotein J and leptin levels in patients with coronary heart disease

In Vivo

Volumn 22, Issue 4, 2008, Pages 537-542

  Poulakou, Maria V ^a   Paraskevas, Kosmas I ^a,b   Wilson, Mark R ^c   Iliopoulos, Dimitrios C ^a   Tsigris, Christos ^a   Mikhailidis, Dimitri P ^b   Perrea, Despina ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Apolipoprotein J; Atherosclerosis; Clusterin; Coronary artery disease; Leptin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLUSTERIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 48349086617     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Shu W, Lei W and Peng S: Recent development of ischaemic heart disease in sex difference. Postgrad Med J 83: 240-243, 2007.
2. Wenger NK, Shaw LJ and Vaccarino V: Coronary heart disease in women: update 2008. Clin Pharmacol Ther 83: 37-51, 2008.
3. Jones SE and Jomary C: Clusterin. Int J Biochem Cell Biol 34: 427-431, 2002.
4. Jenne DE and Tschopp J: Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 17: 154-159, 1992.
5. Rosenberg ME and Silkensen J: Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 27: 633-645, 1995.
6. Rosenberg ME, Dvergsten J and Correa-Rotter R: Clusterin: an enigmatic protein recruited by diverse stimuli. J Lab Clin Med 121: 205-214, 1993.
7. de Silva HV, Stuart WD, Duvic CR, Wetterau JR, Ray MJ, Ferguson DG, Albers HW, Smith WR and Harmony JA: A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 265: 13240-13247, 1990.
8. Calero M, Tokuda T, Rostagno A, Kumar A, Zlokovic B, Frangione B and Ghiso J: Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J 344: 375-383, 1999.
9. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G and Tschopp J: Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 266: 11030-11036, 1991.
10. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC and Harmony JA: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33: 832-839, 1994.
11. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM and La Du BN: Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99: 2005-2019, 1997.
12. Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A and Gonos ES: Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 37: 1175-1187, 2002.
13. Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, Ishii J, Tsuji M, Iwasaki T, Sasaguri Y, Fujioka T, Saito S, Tsushima M, Maruyama T, Miller IP, Miller NE and Egashira T: Serum apolipoprotein J in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 13: 314-322, 2006.
14. Poulakou MV, Paraskevas KI, Vlachos IS, Karabina SP, Wilson MR, Iliopoulos DC, Tsitsilonis SI, Mikhailidis DP and Perrea DN: Effect of statins on serum apolipoprotein J and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology, in press, 2008.
15. Jordan-Starck TC, Lund SD, Witte DP, Aronow BJ, Ley CA, Stuart WD, Swertfeger DK, Clayton LR, Sells SF, Paigen B and Harmony JA: Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J Lipid Res 35: 194-210, 1994.
16. Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, Asuwa N, Choi-Miura NH and Tomita M: Distribution and synthesis of apolipoprotein J in atherosclerotic aorta. Arterioscler Thromb Vasc Biol 18: 665-672, 1998.
17. Ishikawa Y, Ishii T, Akasaka Y, Masuda T, Strong JP, Zieske AW, Takei H, Malcom GT, Taniyama M, Choi-Miura NH and Tomita M: Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis 158: 215-225, 2001.
18. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.
19. Fantuzzi G and Mazzone T: Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 27: 996-1003, 2007.
20. Paraskevas KI. Liapis CD and Mikhailidis DP: Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 7: 761-771, 2006.
21. Beltowski J: Leptin and atherosclerosis. Atherosclerosis 189: 47-60, 2006.
22. Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K and Olsson T: Leptin is associated with increased risk of myocardial infarction. J Intern Med 246: 409-418, 1999.
23. Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L, Hallmans G and Olsson T: Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 30: 328-337, 1999.
24. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A and Sattar N: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104: 3052-3056, 2001.
25. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD and Somers VK: Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 44: 1819-1824, 2004.
26. Hoefle G, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P and Drexel H: Leptin, leptin soluble receptor and coronary atherosclerosis. Eur J Clin Invest 37: 629-636, 2007.
27. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications Part I: Report of a WHO Consultation: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 2006: http://www.who.int/diabetes/ publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
28. Wilson MR, Roeth PJ and Easterbrook-Smith SB: Clusterin enhances the formation of insoluble immune complexes. Biochem Biophys Res Commun 177: 985-990, 1991.
29. Katrinchak C and Fritz K: Clinical implications of C-reactive protein as a predictor of vascular risk. J Am Acad Nurse Pract 19: 335-340, 2007
30. Tsiara S, Elisaf M and Mikhailidis DP: Early vascular benefits of statin therapy. Curr Med Res Opin 19: 540-546, 2003.
31. Abraham J, Campbell CY, Cheema A, Gluckman TJ, Blumenthal RS and Danyi P: C-reactive protein in cardiovascular risk assessment: a review of the evidence. J Cardiometab Syndr 2: 119-123, 2007.
32. Paraskevas KI and Mikhailidis DP: C-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin 24: 75-78, 2008.
33. Inoue N: Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 6: 227-231, 2006.
34. Savkovic V, Gantzer H, Reiser U, Selig L, Gaiser S, Sack U, Kloppel G, Mossner J, Keim V, Horn F and Bodeker H: Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem Biophys Res Commun 356: 431-437, 2007.
35. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, Giorgino R and De Pergola G: Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 25: 805-810, 2001.
36. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ and Kimmel SE: Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89: 3872-3878, 2004.
37. Stejskal D, Ruzicka V and Bartek J: Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent). Vnitr Lek 44: 582-587, 1998 (in Czech).
38. Zhao SP and Wu ZH: Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta 360: 133-140, 2005.
39. Oda A, Taniguchi T and Yokoyama M: Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47: 141-150, 2001.
40. Parhami F, Tintut Y, Ballard A, Fogelman AM and Demer LL: Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 88: 954-960, 2001.
41. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M and Brownlee M: Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276: 25096-25100, 2001.
42. Konstantinides S, Schafer K, Koschnick S and Loskutoff DJ: Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 108: 1533-1540, 2001.
43. Sivamurthy N, Stone DH, LoGerfo FW and Quist WC: Apolipoprotein J inhibits the migration, adhesion and proliferation of vascular smooth muscle cells. J Vasc Surg 34: 716-723, 2001.
44. Michel D, Chatelain G, North S and Bran G: Stress-induced transcription of the clusterin/apoJ gene. Biochem J 328: 45-50, 1997.
45. Strocchi P, Smith MA, Perry G, Tamagno E, Danni O, Pession A, Gaiba A and Dozza B: Clusterin up-regulation following sublethal oxidative stress and lipid peroxidation in human neuroblastoma cells. Neurobiol Aging 27: 1588-1594, 2006.
46. Bajari TM, Strasser V, Nimpf J and Schneider WJ: A model for modulation of leptin activity by association with clusterin. FASEB J 17: 1505-1507, 2003.